濮阳东方妇科医院做人流手术很权威(濮阳东方医院男科治疗早泄评价好收费低) (今日更新中)

EL CAJON, Calif. (KGTV) - A man was hurt after the truck he was driving crashed into a cable pole and overturned at an El Cajon intersection. 149

Dozens of common breakfast cereals and snack bars have trace amounts of a controversial herbicide found in the weed killer Roundup, according to a report released today by an environmental advocacy group.The Environmental Working Group (EWG) found that 26 of the 28 products it tested had levels of Roundup's main ingredient, glyphosate, that were "higher than what EWG scientists consider protective of children's health." An earlier report found similar results in over thirty oat-based foods.List: The name-brand breakfast cereals and snack bars that contain weed killer chemicalManufacturers say their products are safe, but the EWG report argues that the vast majority of foods tested -- such as Honey Nut Cheerios and Quaker Simply Granola Oats -- have glyphosate levels that might pose a cancer risk with long-term consumption.None of the foods violated EPA limits on the herbicide, but the EWG uses a far more conservative health benchmark. California's proposed glyphosate limit, which would be the most restrictive in the country, still allows for glyphosate levels that are over a hundred times higher than the EWG's threshold.The environmental group says its lower threshold includes an added buffer for children, as "exposure during early life can have more significant effects on development later in life," according to Dr. Alexis Temkin, the lead scientist on EWG report.But manufacturers dispute that threshold. Quaker said in a statement that the "EWG report artificially creates a 'safe level' for glyphosate that is detached from those that have been established by responsible regulatory bodies in an effort to grab headlines." 1656

Driving down a dirt logging road in rural Maine, paramedic Nathan Yerxa can’t help but take in the view most days. Looking out over the landscape here, it’s as if the sky and the land seem to merge.Yerxa is a paramedic for North East Mobile Health Services and stationed in Jackman, Maine, a small town in the northern part of this state home to about 700 people. From the edge of town, you can see the Canadian border in the distance, and on any given day, paramedics here are responsible for covering an area that’s approximately the size of the state of Rhode Island.“The remote landscape and difficult terrain make it difficult to bring resources to the area,” Yerxa said, as he drove through town in a Ford pickup truck that’s been converted to an all-terrain ambulance.Like rural communities across the country, getting patients to an emergency room in this area is a difficult, often time-consuming task. The closest ER is about 70 miles away, a trip that can sometimes take close to two hours. While Jackman does have a community health center, the facility can’t perform many emergency procedures most larger hospitals can.So, in an effort to save time and lives, the emergency room is being brought to Jackman in an innovative new way, harnessing technology and the expertise of paramedics likes Yerxa.“I think it’s one of those situations where what’s old is new again,” he said.The idea is a Critical Access Integrated Paramedic program. Paramedics here are receiving more training in critical care. While at the same time, that pickup truck Yerxa relies on is being outfitted with tools like satellite internet and a satellite phone. First responders even have heart rate monitors that can send data wirelessly to a doctor anywhere.The concept is simple. Using technology, paramedics can instantly connect to a doctor no matter where they take a call. From stitches to ultrasounds, paramedics in this region are bridging the rural healthcare gap by instantly connecting via video chat to a doctor who may be hours away.“It is in many ways like a high-tech home visit that you might have seen 60 years ago, but we’re also bringing urgent care services with us,” Yerxa explained.Finding new ways for rural communities to connect is a key component to the program's success.Nationwide 25 million people don't have access to broadband.The COVID-19 pandemic has only magnified the issue. In Maine alone, 36,000 telehealth calls were made last month up from 650 the same time last year. Many times, though, patients and doctors have trouble connecting because of poor internet connections.Town manager Victoria Forkus pushed hard for the program.“We were in a way forced to implement this new program early because of COVID,” she said while sitting inside Jackman’s town offices.The whole program is costing Jackman and surrounding communities about 0,000 a year to implement. Some of the money will come from a tax increase, which is no small feat in a town where the median income is just ,000.But out here, the program has overwhelming support.“What’s the dollar amount on one of my neighbors’ lives? What’s the cost of saving a community member? It’s priceless,” Forkus added.The concept of the program is gaining attention across the state.Jim Rogers, with Health Connect Networks based in Maine, is lobbying Congress hard to expand rural broadband connectivity. It’s something he says is now more imperative than ever given the pandemic.“People in these rural communities just don’t have adequate internet to support a telehealth consult,” he said.As for Yerxa, he sees the program as something other rural communities across the country can emulate.“Hopefully, we can now provide 24-hour coverage to patients in any of these rural locations.” 3770

E-cigarette maker Juul Labs says they are planning to make a significant "reduction in force" as it looks to the future.The company announced the move in a statement as it also looks to pull out of some international markets as they "have not provided the kind of return necessary given the cost to continue investing in the market."According to the Wall Street Journal, the company is reportedly looking to lay off about 1,200 employees, nearly half its workforce. Earlier this year, the company laid off 1,000 employees, Forbes reported.Last year, at least four lawsuits were filed against the company claiming its ads were targeting young people.They also stopped selling several flavored products in the United States last year.The company also replaced its CEO last year.The company said they are looking to rebuild trust with its key stakeholders and the public."To better serve our mission, we must prioritize how we use our resources to execute on our long-term, focused approach," the company said in a statement. "This will allow Juul Labs to continue to invest in science and evidence capabilities, access control technologies, and future products in core markets that make up a vast majority of our business. While those investments will not provide short-term revenue, they will help us earn trust and build a company for the long term to advance the potential for harm reduction for adult smokers and combat underage usage." 1446

Dr. Anthony Fauci delivered more good news regarding a potential coronavirus vaccine, indicating some Americans could begin getting vaccinated by the end of this month.During an interview with CNN’s Wolf Blitzer, Fauci, the director of the National Institute of Allergy and Infectious Diseases National Institute of Allergy and Infectious Diseases, said it’s possible a vaccine could begin reaching some Americans by the end of the month, but was confident some would begin getting vaccinated by the end of the year.Fauci’s declaration came on the same day Pfizer said that its Phase 3 vaccine candidate was showing an effectiveness of over 90%. Fauci said the announcement was promising, but a few more questions need to be addressed before it is given approval. Fauci said that things like the vaccine’s durability and effect on the elderly are among concerns that still need to be tackled.“We may have doses that we’re able to give to people by the end of November, beginning of December,” Fauci told CNN’s Blitzer. “Now you have to go through the hoops of making sure all of the I’s are dotted and the T’s are crossed about the safety and regulatory aspects of it, but we would be giving vaccine, very likely, by the end of this year. That is good news.”Last month, the FDA put into place guidelines on approving a vaccine, which was more restrictive than what the White House had hoped for. The FDA noted that a vaccine candidate must be at least 50% effective. Vaccine candidates should include a median follow-up duration of at least two months after completion of the full vaccination regimen to help provide adequate information to assess a vaccine’s risk-benefit.“In addition to outlining our expectations for vaccine sponsors, we also hope the agency's guidance on COVID-19 vaccines helps the public understand our science-based decision-making process that assures vaccine quality, safety and efficacy for any vaccine that is authorized or approved,” Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said.While it is possible some will begin getting vaccinated in the coming weeks or months, questions remain on how soon a majority of the country will have the opportunity to become vaccinated. The first Americans slated to become vaccinated will be health care workers and people with a high risk of coronavirus complications, such as the elderly and those living in assisted living facilities, according to an NPR report.Given that Pfizer’s vaccine candidate is showing a high level of effectiveness, Fauci called the development “extraordinary.”"We know there's light at the end of the tunnel, but that doesn't mean that we're going to give up the important public health measures that we continually still have to do every single day,” Fauci said.While there is urgency for both public health and economic reasons for a vaccine, some experts have expressed concern over the speed of a vaccine and whether the expedited timeline is long enough to demonstrate efficacy.Even though a vaccine could be ready by year’s end, trials will be expected to continue for over a year to monitor for possible side effects.According to the FDA, a typical Phase 3 trial would take one to three years.“NIH is committed to supporting several Phase 3 vaccine trials to increase the odds that one or more will be effective in preventing COVID-19 and put us on the road to recovery from this devastating pandemic,” said NIH Director Francis S. Collins, M.D., Ph.D. “We also know that preventing this disease could require multiple vaccines and we’re investing in those that we believe have the greatest potential for success.”Pfizer said based on current projections, it expects to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. 3823

来源：资阳报